Half of rifampicin-resistant Mycobacterium tuberculosis complex isolated from tuberculosis patients in Sub-Saharan Africa have concomitant resistance to pyrazinamide.
Besides inclusion in 1st line regimens against tuberculosis (TB), pyrazinamide (PZA) is used in 2nd line anti-TB regimens, including in the short regimen for multidrug-resistant TB (MDR-TB) patients. Guidelines and expert opinions are contradictory about inclusion of PZA in case of resistance. Moreo...
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2017-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC5663438?pdf=render |
| _version_ | 1819070631985020928 |
|---|---|
| author | Jean Claude Semuto Ngabonziza Awa Ba Diallo Elisa Tagliani Bassirou Diarra Abalo Essosimna Kadanga Antieme Combo George Togo Aliou Thiam Willem Bram de Rijk Riccardo Alagna Sabine Houeto Fatoumata Ba Anoumou Yaotsè Dagnra Emil Ivan Dissou Affolabi Valérie Schwoebel Arnaud Trebucq Bouke Catherine de Jong Leen Rigouts Géraldine Daneau “Union short MDR-TB regimen study group” |
| author_facet | Jean Claude Semuto Ngabonziza Awa Ba Diallo Elisa Tagliani Bassirou Diarra Abalo Essosimna Kadanga Antieme Combo George Togo Aliou Thiam Willem Bram de Rijk Riccardo Alagna Sabine Houeto Fatoumata Ba Anoumou Yaotsè Dagnra Emil Ivan Dissou Affolabi Valérie Schwoebel Arnaud Trebucq Bouke Catherine de Jong Leen Rigouts Géraldine Daneau “Union short MDR-TB regimen study group” |
| author_sort | Jean Claude Semuto Ngabonziza |
| collection | DOAJ |
| description | Besides inclusion in 1st line regimens against tuberculosis (TB), pyrazinamide (PZA) is used in 2nd line anti-TB regimens, including in the short regimen for multidrug-resistant TB (MDR-TB) patients. Guidelines and expert opinions are contradictory about inclusion of PZA in case of resistance. Moreover, drug susceptibility testing (DST) for PZA is not often applied in routine testing, and the prevalence of resistance is unknown in several regions, including in most African countries.Six hundred and twenty-three culture isolates from rifampicin-resistant (RR) patients were collected in twelve Sub-Saharan African countries. Among those isolates, 71% were from patients included in the study on the Union short-course regimen for MDR-TB in Benin, Burkina Faso, Burundi, Cameroon, Central Africa Republic, the Democratic Republic of the Congo, Ivory Coast, Niger, and Rwanda PZA resistance, and the rest (29%) were consecutive isolates systematically stored from 2014-2015 in Mali, Rwanda, Senegal, and Togo. Besides national guidelines, the isolates were tested for PZA resistance through pncA gene sequencing.Over half of these RR-TB isolates (54%) showed a mutation in the pncA gene, with a significant heterogeneity between countries. Isolates with fluoroquinolone resistance (but not with injectable resistance or XDR) were more likely to have concurrent PZA resistance. The pattern of mutations in the pncA gene was quite diverse, although some isolates with an identical pattern of mutations in pncA and other drug-related genes were isolated from the same reference center, suggesting possible transmission of these strains.Similar to findings in other regions, more than half of the patients having RR-TB in West and Central Africa present concomitant resistance to PZA. Further investigations are needed to understand the relation between resistance to PZA and resistance to fluoroquinolones, and whether continued use of PZA in the face of PZA resistance provides clinical benefit to the patients. |
| first_indexed | 2024-12-21T17:09:01Z |
| format | Article |
| id | doaj.art-8ba3bf05f6a04070aad504423497ccab |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-21T17:09:01Z |
| publishDate | 2017-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-8ba3bf05f6a04070aad504423497ccab2022-12-21T18:56:27ZengPublic Library of Science (PLoS)PLoS ONE1932-62032017-01-011210e018721110.1371/journal.pone.0187211Half of rifampicin-resistant Mycobacterium tuberculosis complex isolated from tuberculosis patients in Sub-Saharan Africa have concomitant resistance to pyrazinamide.Jean Claude Semuto NgabonzizaAwa Ba DialloElisa TaglianiBassirou DiarraAbalo Essosimna KadangaAntieme Combo George TogoAliou ThiamWillem Bram de RijkRiccardo AlagnaSabine HouetoFatoumata BaAnoumou Yaotsè DagnraEmil IvanDissou AffolabiValérie SchwoebelArnaud TrebucqBouke Catherine de JongLeen RigoutsGéraldine Daneau“Union short MDR-TB regimen study group”Besides inclusion in 1st line regimens against tuberculosis (TB), pyrazinamide (PZA) is used in 2nd line anti-TB regimens, including in the short regimen for multidrug-resistant TB (MDR-TB) patients. Guidelines and expert opinions are contradictory about inclusion of PZA in case of resistance. Moreover, drug susceptibility testing (DST) for PZA is not often applied in routine testing, and the prevalence of resistance is unknown in several regions, including in most African countries.Six hundred and twenty-three culture isolates from rifampicin-resistant (RR) patients were collected in twelve Sub-Saharan African countries. Among those isolates, 71% were from patients included in the study on the Union short-course regimen for MDR-TB in Benin, Burkina Faso, Burundi, Cameroon, Central Africa Republic, the Democratic Republic of the Congo, Ivory Coast, Niger, and Rwanda PZA resistance, and the rest (29%) were consecutive isolates systematically stored from 2014-2015 in Mali, Rwanda, Senegal, and Togo. Besides national guidelines, the isolates were tested for PZA resistance through pncA gene sequencing.Over half of these RR-TB isolates (54%) showed a mutation in the pncA gene, with a significant heterogeneity between countries. Isolates with fluoroquinolone resistance (but not with injectable resistance or XDR) were more likely to have concurrent PZA resistance. The pattern of mutations in the pncA gene was quite diverse, although some isolates with an identical pattern of mutations in pncA and other drug-related genes were isolated from the same reference center, suggesting possible transmission of these strains.Similar to findings in other regions, more than half of the patients having RR-TB in West and Central Africa present concomitant resistance to PZA. Further investigations are needed to understand the relation between resistance to PZA and resistance to fluoroquinolones, and whether continued use of PZA in the face of PZA resistance provides clinical benefit to the patients.http://europepmc.org/articles/PMC5663438?pdf=render |
| spellingShingle | Jean Claude Semuto Ngabonziza Awa Ba Diallo Elisa Tagliani Bassirou Diarra Abalo Essosimna Kadanga Antieme Combo George Togo Aliou Thiam Willem Bram de Rijk Riccardo Alagna Sabine Houeto Fatoumata Ba Anoumou Yaotsè Dagnra Emil Ivan Dissou Affolabi Valérie Schwoebel Arnaud Trebucq Bouke Catherine de Jong Leen Rigouts Géraldine Daneau “Union short MDR-TB regimen study group” Half of rifampicin-resistant Mycobacterium tuberculosis complex isolated from tuberculosis patients in Sub-Saharan Africa have concomitant resistance to pyrazinamide. PLoS ONE |
| title | Half of rifampicin-resistant Mycobacterium tuberculosis complex isolated from tuberculosis patients in Sub-Saharan Africa have concomitant resistance to pyrazinamide. |
| title_full | Half of rifampicin-resistant Mycobacterium tuberculosis complex isolated from tuberculosis patients in Sub-Saharan Africa have concomitant resistance to pyrazinamide. |
| title_fullStr | Half of rifampicin-resistant Mycobacterium tuberculosis complex isolated from tuberculosis patients in Sub-Saharan Africa have concomitant resistance to pyrazinamide. |
| title_full_unstemmed | Half of rifampicin-resistant Mycobacterium tuberculosis complex isolated from tuberculosis patients in Sub-Saharan Africa have concomitant resistance to pyrazinamide. |
| title_short | Half of rifampicin-resistant Mycobacterium tuberculosis complex isolated from tuberculosis patients in Sub-Saharan Africa have concomitant resistance to pyrazinamide. |
| title_sort | half of rifampicin resistant mycobacterium tuberculosis complex isolated from tuberculosis patients in sub saharan africa have concomitant resistance to pyrazinamide |
| url | http://europepmc.org/articles/PMC5663438?pdf=render |
| work_keys_str_mv | AT jeanclaudesemutongabonziza halfofrifampicinresistantmycobacteriumtuberculosiscomplexisolatedfromtuberculosispatientsinsubsaharanafricahaveconcomitantresistancetopyrazinamide AT awabadiallo halfofrifampicinresistantmycobacteriumtuberculosiscomplexisolatedfromtuberculosispatientsinsubsaharanafricahaveconcomitantresistancetopyrazinamide AT elisatagliani halfofrifampicinresistantmycobacteriumtuberculosiscomplexisolatedfromtuberculosispatientsinsubsaharanafricahaveconcomitantresistancetopyrazinamide AT bassiroudiarra halfofrifampicinresistantmycobacteriumtuberculosiscomplexisolatedfromtuberculosispatientsinsubsaharanafricahaveconcomitantresistancetopyrazinamide AT abaloessosimnakadanga halfofrifampicinresistantmycobacteriumtuberculosiscomplexisolatedfromtuberculosispatientsinsubsaharanafricahaveconcomitantresistancetopyrazinamide AT antiemecombogeorgetogo halfofrifampicinresistantmycobacteriumtuberculosiscomplexisolatedfromtuberculosispatientsinsubsaharanafricahaveconcomitantresistancetopyrazinamide AT aliouthiam halfofrifampicinresistantmycobacteriumtuberculosiscomplexisolatedfromtuberculosispatientsinsubsaharanafricahaveconcomitantresistancetopyrazinamide AT willembramderijk halfofrifampicinresistantmycobacteriumtuberculosiscomplexisolatedfromtuberculosispatientsinsubsaharanafricahaveconcomitantresistancetopyrazinamide AT riccardoalagna halfofrifampicinresistantmycobacteriumtuberculosiscomplexisolatedfromtuberculosispatientsinsubsaharanafricahaveconcomitantresistancetopyrazinamide AT sabinehoueto halfofrifampicinresistantmycobacteriumtuberculosiscomplexisolatedfromtuberculosispatientsinsubsaharanafricahaveconcomitantresistancetopyrazinamide AT fatoumataba halfofrifampicinresistantmycobacteriumtuberculosiscomplexisolatedfromtuberculosispatientsinsubsaharanafricahaveconcomitantresistancetopyrazinamide AT anoumouyaotsedagnra halfofrifampicinresistantmycobacteriumtuberculosiscomplexisolatedfromtuberculosispatientsinsubsaharanafricahaveconcomitantresistancetopyrazinamide AT emilivan halfofrifampicinresistantmycobacteriumtuberculosiscomplexisolatedfromtuberculosispatientsinsubsaharanafricahaveconcomitantresistancetopyrazinamide AT dissouaffolabi halfofrifampicinresistantmycobacteriumtuberculosiscomplexisolatedfromtuberculosispatientsinsubsaharanafricahaveconcomitantresistancetopyrazinamide AT valerieschwoebel halfofrifampicinresistantmycobacteriumtuberculosiscomplexisolatedfromtuberculosispatientsinsubsaharanafricahaveconcomitantresistancetopyrazinamide AT arnaudtrebucq halfofrifampicinresistantmycobacteriumtuberculosiscomplexisolatedfromtuberculosispatientsinsubsaharanafricahaveconcomitantresistancetopyrazinamide AT boukecatherinedejong halfofrifampicinresistantmycobacteriumtuberculosiscomplexisolatedfromtuberculosispatientsinsubsaharanafricahaveconcomitantresistancetopyrazinamide AT leenrigouts halfofrifampicinresistantmycobacteriumtuberculosiscomplexisolatedfromtuberculosispatientsinsubsaharanafricahaveconcomitantresistancetopyrazinamide AT geraldinedaneau halfofrifampicinresistantmycobacteriumtuberculosiscomplexisolatedfromtuberculosispatientsinsubsaharanafricahaveconcomitantresistancetopyrazinamide AT unionshortmdrtbregimenstudygroup halfofrifampicinresistantmycobacteriumtuberculosiscomplexisolatedfromtuberculosispatientsinsubsaharanafricahaveconcomitantresistancetopyrazinamide |